Johnson and Johnson (JNJ) is a US based pharma and healthcare company. The company has three primary business segments – consumer products, pharmaceuticals and medical devices.

The company had a revenue of 63 billion USD in 2008. The Consumer segment includes a broad range of products used in the baby care, skin care, oral care, wound care and women’s health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal,hematology, immunology, neurology, oncology etc . The Medical Devices and Diagnostics segment includes a broad range of products such as Cordis’ circulatory disease management products; DePuy’s orthopaedic  products; Ethicon’s surgical care  products ; Ortho-Clinical Diagnostics’ professional diagnostic products and Vistakon’s disposable contact lenses.

The company operates globaly in a predominantly decentralised structure with over 118000 employees.

The consumer segment had a global sale of 16 Billion in 2008  with a 10.8% growth. The company also acquired the consumer healthcare business of pfizer in 2007. The consumer segment had an operating profit of 16.7%, an increase of 1% over 2007.

The pharma segment had a sale of 24.6 billion in 2008, a decrease of around 1.2% over 2007. This business saw an increase in operating profit from 26.3% to 31% mainly due to writedowns in 2007.

The medical devices segment had sales of 23.1 billion with an increase of 6.4% over 2007. The operating profit increased from 22.3% to 31.2% in 2008 partly due to some litigation settlements in 2008 and some restructuring charges in 2007.

The company has maintained a high level of R&D investment (around 10% of sales or higher) during this period. This efficiency of this investment is evident from the drug pipeline of the company which consists of around 18 drugs filed or approved and almost 25 in the stage III trails.

On an aggregate basis, the company has has a very steady performance in the last 10 years and more. The ROE has ranged between 26-30% during this period. This improvement has been driven by an improvement in net margins from around 15% to 20%. The various asset ratios such as working capital turns has improved from low teens to around 30. The fixed asset turns has improved during this period too.

The company has maintained a healthy cash flow during this period and has had a dividend payout of almost 40% during this period. The balance cash has been used to pay off the small amounts of debt, invest in assets and make targeted accquisitions.The company is a zero (net basis) debt company and has a cash flow rate in excess of 10 billion per annum.

JNJ has several key positives as a business and over other pharma companies
–        The company derieves around 30-32% of its revenue and around 40-45% of operating profits from the pharma business segment. Although the company faces the risk of its top performing drugs going off patent, the company has a healthy pipeline to manage this risk
–        The company has a medical devices division which does not face the generic or patent risk of the pharma division and is fairly profitable.
–        The company has a consumer products division with strong brands and an extensive distribution network which act as a hedge to the other segments.
–        The company has a deep moat in all its business segments and sustaniable competitive advantage.
–        The company has a decentralised operating structure with 250 operating companies across 57 countries across the the globe.
–        The company has strong balance sheet and consistent cash flows. The net profit and cash flow has grown at around 16% per annum for the last 10 years. In addition the company has improved its ROE and other asset ratios

The company faces the following key risks
–        Several key pharma brands (in excess of 1 bn sales) such as risperdal and Topamax have lost patent protection in the recent and will face drop in sales and profits due to generics. Success of new drugs is not a given and only a few drugs in the pipeline may replace these blockbusters. In addition, there may be short to medium term dip before the new drugs replace the loss in sales.
–        The global slowdown is likely to impact the topline and bottom line growth for the next 2-3 years
–        The US market accounts for almost 14 bn in sales for the pharma division and 10Bn in sales for the medical devices division. Although I have not been able to find the numbers. the profitability of these divisions in the US is fairly high. This may be at risk due to the health care reforms in the US.
–        The recession in the developed markets which account for major part of the sales and profit could keep the topline and bottom line subdued for the next few years.
–        The company faces litigation risks related to product marketing, pricing, product side effects and patent issues. These risks are detailed over 3 pages of the annual report and are not easily quantifiable. The company has accrued liabilities against these risk and has stated that these risks in aggregate will not have a material effect on the financials.

Next post : competitive analysis, Management quality, valuation and conclusion


  1. Sachin says:

    Hi Rohit, I am just wondering if you have ever looked at Indraprastha Gas Limited and if yes what are your thougts on it. I am seeing it as 50% discount at very hight level. Could you please comment.


  2. admin says:

    Hi sachin
    i have analysed IGL in the past – around 2007-2008. however at that point i felt that the net margins were at risk due to the subsidized pricing and hence did not buy IGL. I have not looked at IGL since then. however IGL is a good company with a good business

    you can find my analysis of IGL on this blog by doing a search via the search button


  3. Sachin says:



Leave a Reply